DOACs – advances and limitations in real world

Thrombosis Journal

Table 1 Pharmacological properties of the DOACs

	Dabigatran [9, 38]	Rivaroxaban [9, 40, 41]	Apixaban [9, 37]	Edoxaban [9, 39]
Target	Factor IIa	Factor Xa	Factor Xa	Factor Xa
Half-life (hour)	12-17	5-9	12	6-10
Time to peak effect (hour)	1-3	2-4	1-3	1-2
Renal clearance as unchanged drug (%)	80	33	27	50
Drug Interactions Pathways	P-gp	3A4/P-gp	3A4/P-gp	3A4/P-gp
Dosing in non-valvular AF	150 mg BID	20 mg OD	5 mg BID	60 mg OD
Dosing in VTE treatment	150 mg BID after 5-10 days of parenteral anticoagulation	15 mg BID for 21 days followed by 20 mg OD	10 mg BID for 7 days followed by 5 mg BID	60 mg OD after 5 days of parenteral anticoagulation

OD-once daily, BID-twice daily, P-gp – P-glycoprotein, 3A4 – cytochrome P450 3A4 isoenzyme

ISSN: 1477-9560